Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI vs FF in Pediatric Asthma
NCT03248128Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of vilanterol in asthma (4 cohorts), sponsored by GSK. Primary endpoints: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (0-4 Hours) at Week 12 and Change From Baseline in Mean Pre-dose Morning Peak Expiratory Flow. Started Oct 2017; status: completed.
02
Drugs
vilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03248128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248128.